Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reform Bill Gives Commissioner Fixed Term, Adds Review Board

Executive Summary

The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act would mandate a fixed six-year term for the FDA commissioner, according to a draft of the bill obtained by “The Pink Sheet.” FDA’s centers would receive a chief medical policy officer.


Related Content

FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit
FDA Succession Planning Targeted In House Legislation
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
What’s In A PDUFA Reauthorization? Maybe These Issues…
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
FDA To Respond To IoM’s Rx Safety Recommendations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts